Fresenius Infringes Sanofi's Eloxatin Patent: Judge

Law360, New York (March 15, 2010, 3:43 PM EDT) -- Sanofi-Aventis US LLC has won summary judgment of infringement against Fresenius Kabi Pharma Ltd., scoring a victory in its bid to keep generic versions of popular colon cancer drug Eloxatin off the market.

Judge Joel Pisano of the U.S. District Court for the District of New Jersey on Friday granted summary judgment to Sanofi, ruling that Fresenius' proposed generic infringes the patent for Eloxatin.

The patent covers a chemical compound for “optically pure oxaliplatin,” the active ingredient in Eloxatin, and Judge Pisano's ruling hinged on the...
To view the full article, register now.